The Biosimilars Forum Applauds SCOTUS Decision to Uphold ACA and US Pathway for Biosimilar Approval
WASHINGTON DC – Meaghan Rose Smith, Executive Director of the Biosimilars Forum, released the following statement following the Supreme Court’s decision in California v. Texas in which the Court voted to uphold the Affordable Care Act:
The Affordable Care Act yet again has been declared the law of the land. The Biosimilars Forum applauds the Supreme Court’s decision to uphold the health care reform law that was designed to reduce the cost of care and improve the lives of all Americans.
Embedded within the ACA is a provision critical to lowering drug costs and expanding patients access to lifechanging treatments, the Biologics Price Competition and Innovation Act (BPCIA). This Act created a regulatory pathway for the FDA to approve biosimilars and is the foundation of biosimilar development. Upholding this law means that millions of patients will continue to have access to biosimilars – lower-cost options for life-saving brand name biologic therapies both now and in the future.
Just a decade after the passage of the ACA, biosimilars are already demonstrating a significant public health benefit. The Biosimilars Forum is encouraged that these therapies will continue to be available.
We encourage Congress to reinforce its commitment to the next generation of generics and the biosimilars market by passing bipartisan legislation that expands access to these cost-saving therapies.